Comparative Pharmacology
Head-to-head clinical analysis: EMADINE versus LASTACAFT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMADINE versus LASTACAFT.
EMADINE vs LASTACAFT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Emedastine is a selective histamine H1 receptor antagonist that inhibits histamine-induced vascular permeability, edema, and pruritus.
Selective histamine H1 receptor antagonist; inhibits mast cell degranulation and reduces release of inflammatory mediators.
1 drop of 0.05% ophthalmic solution in the affected eye(s) twice daily, approximately 8 hours apart.
1 drop in each affected eye twice daily (approximately every 8 hours)
None Documented
None Documented
Terminal elimination half-life: 4–6 hours; clinically, dosing every 4–6 hours as needed for symptom relief
Terminal elimination half-life is approximately 2 hours; clinically, dosing is twice daily.
Renal: approximately 60% as unchanged drug and metabolites; fecal: approximately 15%
Renal: approximately 70% as unchanged drug; fecal: approximately 30% as metabolites.
Category C
Category C
Ophthalmic Antihistamine
Ophthalmic Antihistamine